Screener
Monte Rosa Therapeutics, Inc. GLUE Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:09 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336711
| (in thousands, except share and per share amounts) | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Gain on disposal of property and equipment | — | — | — | 59 |
| Total other income | 5,941 | 4,458 | 11,524 | 8,129 |
| Net (loss) income before income taxes | (43,189) | (11,096) | (87,640) | 36,611 |
| Income tax provision | (208) | (1,199) | (260) | (2,021) |
| Net (loss) income | $(43,397) | $(12,295) | $(87,900) | $34,590 |
| Comprehensive (loss) income: | ||||
| Provision for pension benefit obligation | 54 | 53 | 109 | 101 |
| Unrealized loss on available-for-sale securities | (473) | (97) | (1,447) | (118) |
Item 1. Financial Statements
FAQ
- What is Monte Rosa Therapeutics, Inc.'s income tax?
- Monte Rosa Therapeutics, Inc. (GLUE) reported income tax of $208K in Q2 2026.
- How has Monte Rosa Therapeutics, Inc.'s income tax changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s income tax decreased by 82.7% year-over-year, from $1.2M to $208K.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Monte Rosa Therapeutics, Inc.'s income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude